

David M Charytan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6078183/publications.pdf>

Version: 2024-02-01

113
papers

9,207
citations

101384

36
h-index

42291

92
g-index

115
all docs

115
docs citations

115
times ranked

10999
citing authors

#	ARTICLE	IF	CITATIONS
1	Implantable Loop Recorder Monitoring and the Incidence of Previously Unrecognized Atrial Fibrillation in Patients on Hemodialysis. <i>Kidney International Reports</i> , 2022, 7, 189-199.	0.4	7
2	Obesity Related Glomerulopathy in Adolescent Women: The Effect of Body Surface Area. <i>Kidney360</i> , 2022, 3, 113-121.	0.9	5
3	Kidney Recovery and Death in Critically Ill Patients With COVID-19 Associated Acute Kidney Injury Treated With Dialysis: The STOP-COVID Cohort Study. <i>American Journal of Kidney Diseases</i> , 2022, 79, 404-416.e1.	2.1	23
4	Potential Effects of Elimination of the Black Race Coefficient in eGFR Calculations in the CREDESCENCE Trial. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022, 17, 361-373.	2.2	9
5	The impact of canagliflozin on the risk of neuropathy events: A post-hoc exploratory analysis of the CREDESCENCE trial. <i>Diabetes and Metabolism</i> , 2022, 48, 101331.	1.4	5
6	Cardiovascular Risk Prediction Scores in CKD: What Are We Missing?. <i>Journal of the American Society of Nephrology: JASN</i> , 2022, 33, 462-464.	3.0	2
7	Screening for Cardiovascular Disease in CKD: CON. <i>Kidney360</i> , 2022, 3, 1836-1838.	0.9	0
8	Utilization of Palliative Care for Patients with COVID-19 and Acute Kidney Injury during a COVID-19 Surge. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022, 17, 342-349.	2.2	7
9	Outcomes with revascularization and medical therapy in patients with coronary disease and chronic kidney disease: A meta-analysis. <i>Atherosclerosis</i> , 2022, 351, 41-48.	0.4	7
10	Controlled Study of Decision-Making Algorithms for Kidney Replacement Therapy Initiation in Acute Kidney Injury. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022, 17, 194-204.	2.2	2
11	Automated Determination of Left Ventricular Function Using Electrocardiogram Data in Patients on Maintenance Hemodialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022, 17, 1017-1025.	2.2	3
12	AKI Treated with Renal Replacement Therapy in Critically Ill Patients with COVID-19. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 161-176.	3.0	207
13	A Systematic Review of the Incidence of Arrhythmias in Hemodialysis Patients Undergoing Long-Term Monitoring With Implantable Loop Recorders. <i>Kidney International Reports</i> , 2021, 6, 56-65.	0.4	18
14	The Microbiome and p-Inulin in Hemodialysis: A Feasibility Study. <i>Kidney360</i> , 2021, 2, 445-455.	0.9	3
15	An Exploratory Qualitative Study of Patient and Caregiver Perspectives of Ambulatory Kidney Palliative Care. <i>American Journal of Hospice and Palliative Medicine</i> , 2021, 38, 1242-1249.	0.8	8
16	Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 384-395.	2.2	37
17	Extracorporeal membrane oxygenation in patients with severe respiratory failure from COVID-19. <i>Intensive Care Medicine</i> , 2021, 47, 208-221.	3.9	143
18	Electrolyte Changes in Contemporary Hemodialysis: A Secondary Analysis of the Monitoring in Dialysis Study. <i>Kidney360</i> , 2021, 2, 695-707.	0.9	5

#	ARTICLE	IF	CITATIONS
19	All-Cause Mortality and Progression to End-Stage Kidney Disease Following Percutaneous Revascularization or Surgical Coronary Revascularization in Patients with CKD. <i>Kidney International Reports</i> , 2021, 6, 1580-1591.	0.4	3
20	Cost-Effectiveness of Coronary Artery Bypass Grafting and Percutaneous Coronary Intervention in Patients With Chronic Kidney Disease and Acute Coronary Syndromes in the US Medicare Program. <i>Journal of the American Heart Association</i> , 2021, 10, e019391.	1.6	3
21	Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial. <i>American Heart Journal</i> , 2021, 233, 141-148.	1.2	30
22	The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: Analysis of the CREDENCE trial. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1652-1659.	2.2	6
23	Decreasing Incidence of Acute Kidney Injury in Patients with COVID-19 Critical Illness in New York City. <i>Kidney International Reports</i> , 2021, 6, 916-927.	0.4	45
24	Prasugrel and Ticagrelor in Patients with Drug-Eluting Stents and Kidney Failure. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 757-764.	2.2	11
25	Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease. <i>Circulation</i> , 2021, 143, 1735-1749.	1.6	60
26	Outcomes among Hospitalized Chronic Kidney Disease Patients with COVID-19. <i>Kidney360</i> , 2021, 2, 1107-1114.	0.9	5
27	Mineralocorticoid Receptor Antagonists and Cardiovascular Health with Kidney Failure. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 843-845.	2.2	0
28	Serum Biomarkers of Iron Stores Are Associated with Increased Risk of All-Cause Mortality and Cardiovascular Events in Nondialysis CKD Patients, with or without Anemia. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 2020-2030.	3.0	37
29	Hospital-Level Variation in Death for Critically Ill Patients with COVID-19. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 204, 403-411.	2.5	39
30	Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial. <i>European Heart Journal</i> , 2021, 42, 4891-4901.	1.0	80
31	Obesity, inflammatory and thrombotic markers, and major clinical outcomes in critically ill patients with COVID-19 in the US. <i>Obesity</i> , 2021, 29, 1719-1730.	1.5	11
32	Patient Activation Measure in Dialysis Dependent Patients in the United States. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, , ASN.2021030315.	3.0	5
33	Long-term outcomes of patients with stable coronary disease and chronic kidney dysfunction: 10-year follow-up of the Medicine, Angioplasty, or Surgery Study II Trial. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 1369-1376.	0.4	13
34	Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2020, 97, 42-61.	2.6	260
35	Coronary Microvascular Dysfunction, Left Ventricular Remodeling, and Clinical Outcomes in Patients With Chronic Kidney Impairment. <i>Circulation</i> , 2020, 141, 21-33.	1.6	54
36	In-hospital cardiac arrest in critically ill patients with covid-19: multicenter cohort study. <i>BMJ, The</i> , 2020, 371, m3513.	3.0	108

#	ARTICLE	IF	CITATIONS
37	Early Change in Albuminuria with Canagliflozin Predicts Kidney and Cardiovascular Outcomes: A Post Hoc Analysis from the CREDENCE Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 2925-2936.	3.0	82
38	P1019CANAGLIFLOZIN AND RISK OF SKIN AND SOFT TISSUE INFECTIONS IN PEOPLE WITH DIABETES MELLITUS AND KIDNEY DISEASE - A POST-HOC ANALYSIS OF THE CREDENCE TRIAL. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.4	0
39	Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m2. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 1705-1714.	2.2	87
40	Megakaryocytes and platelet-fibrin thrombi characterize multi-organ thrombosis at autopsy in COVID-19: A case series. <i>EClinicalMedicine</i> , 2020, 24, 100434.	3.2	465
41	Direct oral anticoagulants in chronic kidney disease: an update. <i>Current Opinion in Nephrology and Hypertension</i> , 2020, 29, 489-496.	1.0	9
42	P1013CANAGLIFLOZIN AND RISK OF GENITAL INFECTIONS AND URINARY TRACT INFECTIONS IN PEOPLE WITH DIABETES MELLITUS AND KIDNEY DISEASE- A POST-HOC ANALYSIS OF THE CREDENCE TRIAL. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.4	0
43	Combination Hydralazine and Isosorbide Dinitrate in Dialysis-Dependent ESRD (HIDE): A Randomized, Placebo-Controlled, Pilot Trial. <i>Kidney360</i> , 2020, 1, 1380-1389.	0.9	2
44	Nephrology and COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 1137.	3.8	15
45	Cardiovascular Issues Among Homeless People: An Issue that Needs Attention. <i>Clinical Medicine Insights: Cardiology</i> , 2020, 14, 117954682097503.	0.6	1
46	Serum glucose and phosphorus concentrations during continuous renal replacement therapy using commercial replacement solutions with or without phosphorus. <i>Hemodialysis International</i> , 2020, 24, 330-334.	0.4	4
47	Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 1128-1139.	3.0	106
48	Oxalate Nephropathy in an Oxalobacter formigenes-“Negative Subject. <i>Kidney International Reports</i> , 2020, 5, 754-757.	0.4	5
49	Accelerated Venovenous Hemofiltration as a Transitional Renal Replacement Therapy in the Intensive Care Unit. <i>American Journal of Nephrology</i> , 2020, 51, 318-326.	1.4	15
50	Impending Shortages of Kidney Replacement Therapy for COVID-19 Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 880-882.	2.2	101
51	Acute Peritoneal Dialysis During the COVID-19 Pandemic at Bellevue Hospital in New York City. <i>Kidney360</i> , 2020, 1, 1345-1352.	0.9	11
52	Cobalt alloy hip prostheses and new-onset heart failure in patients with and without chronic kidney disease. <i>Clinical Nephrology</i> , 2020, 94, 215-216.	0.4	0
53	Comparative Utilization and Temporal Trends in Cardiac Stress Testing in U.S. Medicare Beneficiaries With and Without Chronic Kidney Disease. <i>JACC: Cardiovascular Imaging</i> , 2019, 12, 1420-1426.	2.3	20
54	Identification of ESRD in Cardiovascular Procedural Databases. <i>Kidney International Reports</i> , 2019, 4, 1477-1482.	0.4	0

#	ARTICLE	IF	CITATIONS
55	Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups. <i>Circulation</i> , 2019, 140, 739-750.	1.6	211
56	Comparative Effectiveness of Medical Therapy, Percutaneous Revascularization, and Surgical Coronary Revascularization in Cardiovascular Risk Subgroups of Patients With CKD: A Retrospective Cohort Study of Medicare Beneficiaries. <i>American Journal of Kidney Diseases</i> , 2019, 74, 463-473.	2.1	14
57	SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 845-854.	5.5	595
58	Association of Chronic Kidney Disease with Preserved Ejection Fraction Heart Failure Is Independent of Baseline Cardiac Function. <i>Kidney and Blood Pressure Research</i> , 2019, 44, 1247-1258.	0.9	13
59	Chronic kidney disease and valvular heart disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2019, 96, 836-849.	2.6	80
60	Chronic Kidney Disease and Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1823-1838.	1.2	403
61	Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1199-1208.	2.2	83
62	Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER Trial. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2961-2970.	1.2	115
63	Duration of Dual Antiplatelet Therapy in Patients with CKD and Drug-Eluting Stents. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019, 14, 810-822.	2.2	18
64	Relationship between dialytic parameters and reviewer confirmed arrhythmias in hemodialysis patients in the monitoring in dialysis study. <i>BMC Nephrology</i> , 2019, 20, 80.	0.8	23
65	Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. <i>New England Journal of Medicine</i> , 2019, 380, 2295-2306.	13.9	3,760
66	Relation of Serum and Urine Renal Biomarkers to Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Recent Acute Coronary Syndromes (From the EXAMINE Trial). <i>American Journal of Cardiology</i> , 2019, 123, 382-391.	0.7	12
67	Safety and cardiovascular efficacy of spironolactone in dialysis-dependent ESRD (SPin-D): a randomized, placebo-controlled, multiple dosage trial. <i>Kidney International</i> , 2019, 95, 973-982.	2.6	70
68	The axis of local cardiac endogenous Klotho-TGF- β 1-Wnt signaling mediates cardiac fibrosis in human. <i>Journal of Molecular and Cellular Cardiology</i> , 2019, 136, 113-124.	0.9	32
69	Primary outcomes of the Monitoring in Dialysis Study indicate that clinically significant arrhythmias are common in hemodialysis patients and related to dialytic cycle. <i>Kidney International</i> , 2018, 93, 941-951.	2.6	139
70	Coronary flow reserve is predictive of the risk of cardiovascular death regardless of chronic kidney disease stage. <i>Kidney International</i> , 2018, 93, 501-509.	2.6	59
71	Association of Changes in Creatinine and Potassium Levels After Initiation of Renin Angiotensin Aldosterone System Inhibitors With Emergency Department Visits, Hospitalizations, and Mortality in Individuals With Chronic Kidney Disease. <i>JAMA Network Open</i> , 2018, 1, e183874.	2.8	11
72	Extracorporeal Stromal Cell Therapy for Subjects With Dialysis-Dependent Acute Kidney Injury. <i>Kidney International Reports</i> , 2018, 3, 1119-1127.	0.4	12

#	ARTICLE	IF	CITATIONS
73	The Authors Reply. <i>Kidney International</i> , 2018, 94, 430-431.	2.6	0
74	Echocardiographic parameters and renal outcomes in patients with preserved renal function, and mild- moderate CKD. <i>BMC Nephrology</i> , 2018, 19, 176.	0.8	16
75	A Decision-Making Algorithm for Initiation and Discontinuation of RRT in Severe AKI. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 228-236.	2.2	52
76	Benefit of Ezetimibe Added to Simvastatin in Reduced Kidney Function. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 3034-3043.	3.0	30
77	ESRD After Heart Failure, Myocardial Infarction, or Stroke in Type 2 Diabetic Patients With CKD. <i>American Journal of Kidney Diseases</i> , 2017, 70, 522-531.	2.1	15
78	Epidemiology and Natural History of the Cardiorenal Syndromes in a Cohort with Echocardiography. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 1624-1633.	2.2	29
79	Percutaneous Coronary Intervention Versus Optimal Medical Therapy for Stable Angina in Advanced CKD: A Decision Analysis. <i>American Journal of Kidney Diseases</i> , 2017, 69, 350-357.	2.1	7
80	The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics. <i>American Journal of Nephrology</i> , 2017, 46, 462-472.	1.4	194
81	Early versus late initiation of renal replacement therapy in patients with acute kidney injury: a meta-analysis of randomised clinical trials. <i>Swiss Medical Weekly</i> , 2017, 147, w14507.	0.8	14
82	Spironolactone in Dialysis: What's Old Is New Again. <i>American Journal of Kidney Diseases</i> , 2016, 68, 512-514.	2.1	2
83	Reduced risk of myocardial infarct and revascularization following coronary artery bypass grafting compared with percutaneous coronary intervention in patients with chronic kidney disease. <i>Kidney International</i> , 2016, 90, 411-421.	2.6	38
84	Arrhythmia and Sudden Death in Hemodialysis Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 721-734.	2.2	57
85	Association of circulating angiogenesis inhibitors and asymmetric dimethyl arginine with coronary plaque burden. <i>Fibrogenesis and Tissue Repair</i> , 2015, 8, 13.	3.4	9
86	The Effect of Bicarbonate Administration via Continuous Venovenous Hemofiltration on Acid-Base Parameters in Ventilated Patients. <i>BioMed Research International</i> , 2015, 2015, 1-8.	0.9	5
87	Cause of Death in Patients With Diabetic CKD Enrolled in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). <i>American Journal of Kidney Diseases</i> , 2015, 66, 429-440.	2.1	29
88	Association of activated vitamin D use with myocardial fibrosis and capillary supply: results of an autopsy study. <i>Renal Failure</i> , 2015, 37, 1067-1069.	0.8	4
89	Shades of Grey. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 1107-1109.	2.2	1
90	Cardiorenal Syndrome and the Role of the Bone-Mineral Axis and Anemia. <i>American Journal of Kidney Diseases</i> , 2015, 66, 196-205.	2.1	38

#	ARTICLE	IF	CITATIONS
91	Association between renal function and cardiovascular structure and function in heart failure with preserved ejection fraction. <i>European Heart Journal</i> , 2014, 35, 3442-3451.	1.0	78
92	How is the Heart Best Protected in Chronic Dialysis Patients?. <i>Seminars in Dialysis</i> , 2014, 27, 325-328.	0.7	2
93	Is left ventricular hypertrophy a modifiable risk factor in end-stage renal disease. <i>Current Opinion in Nephrology and Hypertension</i> , 2014, 23, 578-585.	1.0	28
94	Do Implantable Defibrillators Help Patients With CKD?. <i>American Journal of Kidney Diseases</i> , 2014, 64, 4-6.	2.1	4
95	Increased concentration of circulating angiogenesis and nitric oxide inhibitors induces endothelial to mesenchymal transition and myocardial fibrosis in patients with chronic kidney disease. <i>International Journal of Cardiology</i> , 2014, 176, 99-109.	0.8	87
96	Angiographic characteristics of coronary arterial segments progressing to myocardial infarction in patients with and without chronic kidney disease. <i>Clinical and Experimental Nephrology</i> , 2013, 17, 232-239.	0.7	5
97	Risks of Death and Graft Failure After Surgical Versus Percutaneous Coronary Revascularization in Renal Transplant Patients. <i>Journal of the American Heart Association</i> , 2013, 2, e003558.	1.6	5
98	You are what you eat: dietary salt intake and renin-angiotensin blockade in diabetic nephropathy. <i>Kidney International</i> , 2012, 82, 257-259.	2.6	11
99	Risks of Death and End-Stage Renal Disease After Surgical Compared With Percutaneous Coronary Revascularization in Elderly Patients With Chronic Kidney Disease. <i>Circulation</i> , 2012, 126, S164-9.	1.6	58
100	CKD and Coronary Collateral Supply in Individuals Undergoing Coronary Angiography after Myocardial Infarction. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2012, 7, 1079-1086.	2.2	5
101	Circulating Endoglin Concentration Is Not Elevated in Chronic Kidney Disease. <i>PLoS ONE</i> , 2011, 6, e23718.	1.1	6
102	Long-term Clinical Outcomes Following Drug-Eluting or Bare-Metal Stent Placement in Patients With Severely Reduced GFR: Results of the Massachusetts Data Analysis Center (Mass-DAC) State Registry. <i>American Journal of Kidney Diseases</i> , 2011, 57, 202-211.	2.1	28
103	Trends in the Use and Outcomes of Implantable Cardioverter-Defibrillators in Patients Undergoing Dialysis in the United States. <i>American Journal of Kidney Diseases</i> , 2011, 58, 409-417.	2.1	110
104	Location of acute coronary artery thromboses in patients with and without chronic kidney disease. <i>Kidney International</i> , 2009, 75, 80-87.	2.6	19
105	Early Angiography in Patients with Chronic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 1032-1043.	2.2	103
106	Risk of target lesion revascularization after coronary stenting in patients with and without chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2007, 22, 2578-2585.	0.4	11
107	Risks of coronary artery bypass surgery in dialysis-dependent patients—analysis of the 2001 National Inpatient Sample. <i>Nephrology Dialysis Transplantation</i> , 2007, 22, 1665-1671.	0.4	49
108	Distribution of Coronary Artery Disease and Relation to Mortality in Asymptomatic Hemodialysis Patients. <i>American Journal of Kidney Diseases</i> , 2007, 49, 409-416.	2.1	95

#	ARTICLE	IF	CITATIONS
109	The use of invasive cardiac procedures after acute myocardial infarction in long-term dialysis patients. <i>American Heart Journal</i> , 2006, 152, 558-564.	1.2	81
110	Kidney Function and Use of Recommended Medications after Myocardial Infarction in Elderly Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2006, 1, 796-801.	2.2	32
111	Relationship of chronic kidney disease to cardiovascular death and myocardial infarction following coronary stenting. <i>Journal of Nephrology</i> , 2006, 19, 764-70.	0.9	2
112	Relationship of aortic atherosclerosis to acute renal failure following cardiac surgery. <i>Journal of Nephrology</i> , 2006, 19, 628-33.	0.9	1
113	Allograft rejection and glomerular basement membrane antibodies in Alport's syndrome. <i>Journal of Nephrology</i> , 2004, 17, 431-5.	0.9	12